Dermata Therapeutics Holdings Inc. (DRMAW)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Dermata Therapeutics Holdings Inc. (DRMAW) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Dermata Therapeutics Holdings Inc. ever had a stock split?
Dermata Therapeutics Holdings Inc. Profile
| Biotechnology Industry | Healthcare Sector | Gerald T. Proehl CEO | NASDAQ (CM) Exchange | 249845116 CUSIP |
| US Country | 9 Employees | - Last Dividend | - Last Split | 13 Aug 2021 IPO Date |
Overview
Dermata Therapeutics, Inc. is a pioneering clinical-stage medical dermatology company focused on the discovery, development, and eventual market release of novel pharmaceutical products aimed at treating a variety of medical and aesthetic skin conditions and diseases. Since its establishment in 2014, Dermata Therapeutics has dedicated its efforts to address unmet needs within the dermatology community, harnessing cutting-edge science and research to bring forward innovative solutions. The company is headquartered in San Diego, California, reflecting its strategic position within one of the world’s leading biotechnology hubs. Dermata’s commitment to excellence and innovation in dermatological care positions it as a promising player in the field of medical dermatology.
Products and Services
Dermata Therapeutics, Inc. has made significant strides in the development of its pharmaceutical product candidates, focusing on the treatment of both medical and aesthetic skin conditions. The company’s pipeline includes:
- DMT310: This leading product candidate has successfully completed a Phase IIb clinical trial for the treatment of moderate-to-severe acne, demonstrating Dermata’s commitment to tackling prevalent skin conditions with unmet medical needs. Furthermore, DMT310 has also completed a Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, showcasing its potential versatility in treating various dermatological conditions. Currently, DMT310 is undergoing a Phase 2 clinical trial for addressing moderate-to-severe rosacea, further expanding its potential applicability in the dermatologic landscape.
- DMT410: Another innovative product in Dermata’s pipeline, DMT410, has completed Phase Ib POC trials targeting the treatment of axillary hyperhidrosis (excessive underarm sweating) and certain aesthetic conditions. This development signifies Dermata’s venture into addressing both the medical and aesthetic aspects of dermatologic health, indicating a comprehensive approach to skin care.
